ArticleDiscover oncology2025
Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Neoadjuvant therapy for stage II-III triple-negative breast cancer: Current evidence, clinical boundaries and emerging strategies (Review).Oncology letters · 2026Review
- A Rationally Engineered Norfloxacin-Phenoxazine Hybrid as a Dual-Function Anticancer Agent: DNA Intercalation Synergizes with Topoisomerase II Inhibition against Murine Breast Tumor.ACS medicinal chemistry letters · 2026Article
- Novel pyridine-based chalcone analogs and triple negative breast cancer: potential therapy & molecular pathways.Scientific reports · 2026Article
- Bioactive Natural Compounds in Triple-Negative Breast Cancer: Molecular Targets and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Resveratrol as a Modulator of Adriamycin-, Taxol-, and Cisplatin-Induced Cytotoxicity in MCF-7 Breast Cancer Cells.International journal of molecular sciences · 2026Article
- Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study.EClinicalMedicine · 2026Article
- Case Report: Pathologic complete response in triple negative breast cancer treated with anthracycline free regimen.Frontiers in oncology · 2026Article
- Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study examines the effectiveness of platinum-based anthracycline-free neoadjuvant chemotherapy (NAC) combined with taxanes in treating triple-negative breast cancer (TNBC).
methodsStudies published up to January 2025 were systematically retrieved from PubMed, Web of Science, Embase, and the Cochrane Library. A pooled analysis was conducted to assess the pathological complete response (pCR) rate, adverse events (AEs), and survival outcomes. Subgroup analyses were performed to examine the influence of different chemotherapy regimens and patient characteristics on treatment efficacy.
resultsA total of 30 studies involving 3,637 TNBC patients were included in the analysis. The pooled overall survival (OS) rate was 69.92% (95% confidence interval (CI): 41.65%-88.33%), with 2-year, 3-year, and 5-year OS rates of 95.38% (95% CI: 86.64%-98.50%), 94.63% (95% CI: 87.91%-97.71%), and 86.97% (95% CI: 80.76%-91.39%), respectively. Among secondary outcomes, the pooled disease-free survival (DFS) rate was 77.53% (95% CI: 69.54%-83.91%), and the pCR rate was 46.45% (95% CI: 42.55%-50.39%). The most frequently reported hematologic AEs included anemia, neutropenia, and leukopenia, while the most common non-hematologic AEs were nausea and vomiting, along with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Subgroup analyses demonstrated that the combination of docetaxel and carboplatin achieved a higher pCR rate (52.00%) compared to paclitaxel plus carboplatin (42.00%). Concerning geographic origin, the highest pCR rate was observed in patients from the United States (50.00%), followed by Germany (46.00%) and China (40.00%). In terms of OS, the highest survival rate was reported with paclitaxel plus lobaplatin (94.00%), followed by carboplatin (80.00%) and cisplatin (45.00%).
conclusionPlatinum-based anthracycline-free NAC regimens combined with taxanes appear to be both effective and well-tolerated in patients with TNBC. Nevertheless, in the absence of randomized controlled trials (RCTs) directly comparing this approach to anthracycline-based regimens, further investigation is warranted to substantiate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.